文献速递骨质疏松与代谢性骨病

骨负荷运动与利塞膦酸预防低骨量绝经后妇女骨质疏松的随机对照试验

Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
PubMed 文献 · Osteoporos Int · 2021-09-14

结果显示利塞膦酸组脊柱骨密度改善显著优于运动组和对照组,骨转换标志物下降也更明显。结论建议保证钙和维生素D摄入并参与骨负荷运动,加用双膦酸盐可进一步增加骨密度。

要点

  • 利塞膦酸组脊柱骨密度变化显著优于运动组和对照组。
  • 利塞膦酸组骨形成和骨吸收标志物下降幅度大于运动组和对照组。
  • 运动组骨密度变化与对照组差异不显著,但指南仍建议骨负荷运动。

核心结论

  • 绝经后低骨量女性应保证充足的钙和维生素D摄入并参与骨负荷运动。
  • 加用双膦酸盐可增加骨密度,尤其在脊柱部位。

研究设计与样本

  • 干预12个月,分为钙和维生素D对照组、利塞膦酸加钙和维生素D组、骨负荷运动加钙和维生素D组。
  • 在基线、6个月和12个月分析骨密度及血清骨形成标志物Alkphase B和骨吸收标志物Serum Ntx。

主要发现

  • 脊柱骨密度存在组别与时间交互作用,利塞膦酸组改善优于运动组(p ≤ .010)和对照组(p ≤ .001)。
  • 12个月时运动组脊柱、髋部和股骨颈骨密度变化分别为+0.2%、+0.5%和-0.4%。
  • 12个月时对照组脊柱、髋部和股骨颈骨密度变化分别为-0.7%、+0.5%和-0.5%。
  • 利塞膦酸组Alkphase B和Serum Ntx 12个月变化分别为-20.3%和-19.0%,运动组为-6.7%和-7.0%,对照组为-6.3%和-9.0%。

关键数值与推荐

  • 利塞膦酸组与运动组比较Alkphase B下降差异p < .001,与对照组比较p < .001。
  • 利塞膦酸组与运动组比较Serum Ntx下降差异p = .004,与对照组比较p = .007。

临床怎么用

  • 对绝经后低骨量女性,应推荐充足钙和维生素D摄入并鼓励骨负荷运动。
  • 若需进一步增加骨密度,尤其是脊柱部位,可考虑加用双膦酸盐如利塞膦酸。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This randomized controlled trial compared changes in bone mineral density (BMD) and bone turnover in postmenopausal women with low bone mass randomized to 12 months of either risedronate, exercise, or a control group. METHODS: Two hundred seventy-six women with low bone mass, within 6 years of menopause, were included in analysis. Treatment groups were 12 months of (a) calcium and vitamin D supplements (CaD) (control), (b) risedronate + CaD (risedronate), or (c) bone-loading exercises + CaD (exercise). BMD and serum markers for bone formation (Alkphase B) and resorption (Serum Ntx) were analyzed at baseline, 6, and 12 months. RESULTS: Using hierarchical linear modeling, a group by time interaction was found for BMD at the spine, indicating a greater improvement in the risedronate group compared to exercise (p ≤ .010) or control groups (p ≤ .001). At 12 months, for women prescribed risedronate, changes in BMD at the spine, hip, and femoral neck from baseline were + 1.9%, + 0.9%, and + .09%; in exercise group women, + 0.2%, + 0.5%, and - 0.4%; and in control group women, - 0.7%, + 0.5%, and - 0.5%. There were also significant differences in reductions in Alkphase B (RvsE, p < .001, RvsC, p < .001) and Serum Ntx (RvsE, p = .004, RvsC, p = .007) in risedronate women compared to exercise and control groups. For risedronate, 12-month changes in Alkphase B and Serum Ntx were - 20.3% and - 19.0%; for exercise, - 6.7% and - 7.0%; and for control, - 6.3% and - 9.0%. CONCLUSION: Postmenopausal women with low bone mass should obtain adequate calcium and vitamin D and participate in bone-loading exercises. Additional use of BPs will increase BMD, especially at the spine.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Waltman N, Kupzyk KA, Flores LE, et al. Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial. Osteoporos Int. 2021. PMID: 34519832. doi:10.1007/s00198-021-06083-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。